• A novel regulatory mechanism for human interferon lambda has been defined

  • A new graduate student begins her work towards an M.S. at HUMIGEN, graduation expected 2013

  • HUMIGEN opens two new research laboratories, in Lymphocyte Signaling and Cellular Immunology

  • HUMIGEN begins recruiting SLE patients for a novel biomarker discovery study

  • A HUMIGEN Research Associate graduates May 2011 with an M.S. in Molecular Pathology and Immunology

  • HUMIGEN begins recruiting asthma patients for a novel biomarker discovery study

  • A new soluble variant of the human IL-23 receptor inhibits the development of human Th17 cells

  • Two graduate students are working towards their M.S. in HUMIGEN, graduation expected 2012

  • HUMIGEN begins recruiting IBD patients for a novel biomarker discovery study

  • A novel feedback loop between the Th2 response and interferon lambda is mediated by monocytes

  • A new Ph.D. student begins work in HUMIGEN research laboratories


Welcome to HUMIGEN, The Institute for Genetic Immunology.

HUMIGEN is the immunology and inflammation genetics arm of Genesis Biotechnology Group (GBG). Our mission is to understand the relationship between human health, the immune system, and disease pathogenesis and outcome.

HUMIGEN was formed in 2007 with a role to develop a program of translational research into being that would address the role of inflammation in pathogenesis, and understand its genetics. Using this information, we probe disease biology in order to identify targets for therapeutic intervention. Our ultimate goal is to contribute to the diagnosis and treatment of immune system-mediated diseases, and advance human health.

New Article on News-Medical.net
Type 3 interferons and T helper 2 cells: an interview with Grant Gallagher, Managing Director, HUMIGEN

Emergency Closing